Notice: This company has been marked as potentially delisted and may not be actively trading. Melinta Therapeutics (MLNT) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage ProductsOctober 17, 2024 | finance.yahoo.comMelinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology OfficerSeptember 5, 2024 | finance.yahoo.comSWTX SpringWorks Therapeutics, Inc.April 23, 2024 | seekingalpha.comFDA Requests Additional Data for Venatorx and Melinta's Antibiotic CombinationFebruary 28, 2024 | msn.comPromising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIsFebruary 27, 2024 | msn.comVenatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-TaniborbactamFebruary 23, 2024 | finance.yahoo.comCidara, Melinta announce publication of Rezzayo data in medical journalDecember 5, 2023 | msn.comMelinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.November 9, 2023 | finance.yahoo.comMelinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023October 11, 2023 | finance.yahoo.comMelinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)October 2, 2023 | uk.finance.yahoo.comMelinta Therapeutics, Inc.September 26, 2023 | thestreet.comMelinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in CanadaMay 15, 2023 | finance.yahoo.comCidara Therapeutics Sheds Skin, Shifts To ImmunotherapyMarch 1, 2023 | seekingalpha.comBiVictriX Therapeutics reports "really exciting" BCX001 dataFebruary 24, 2023 | finance.yahoo.comOptimizeRx and Melinta Therapeutics Present Third Annual Innovate4Outcomes(R) Healthcare Design Thinking-Inspired EventOctober 20, 2022 | technews.tmcnet.comMelinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.July 27, 2022 | finance.yahoo.comMelinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug DevelopmentOctober 25, 2021 | finance.yahoo.comMelinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)September 20, 2021 | apnews.com Get Melinta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%. Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). MLNT Media Mentions By Week MLNT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLNT News Sentiment▼0.000.43▲Average Medical News Sentiment MLNT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLNT Articles This Week▼00▲MLNT Articles Average Week Get Melinta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CPIX News Today DRRX News Today SYRS News Today CUE News Today IDYA News Today CPRX News Today LLY News Today JNJ News Today ABBV News Today MRK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLNT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melinta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Melinta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
